Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020)
Argenx Se (ARGX) posted quarterly Non-Current Deffered Revenue of $249.5 million for Q4 2020, up 0.56% year-on-year from $248.1 million in Q1 2020, and up 8.24% on a QoQ basis from $230.5 million in Q2 2020.
Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020) Analysis & Trends
Argenx Se (ARGX) has reported Non-Current Deffered Revenue for 4 consecutive years, with $249.5 million the latest figure, recorded in Q4 2020.
- Quarterly Non-Current Deffered Revenue rose 0.56% year-over-year to $249.5 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $249.5 million (up 0.56% YoY) and the FY2020 annual result came in at $269.0 million, up 9.84% from the prior year.
- Non-Current Deffered Revenue rose to $249.5 million in Q4 2020 per ARGX's latest filing, from $230.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for ARGX reached as high as $270.5 million in Q2 2019 and fell as low as $2.1 million in Q4 2017.
- A 4-year average of $169.2 million and a median of $239.3 million in 2020 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue tumbled 85.75% — and 2020, when it rose 0.56%.
- Year by year, Non-Current Deffered Revenue stood at $14.5 million in 2016, then slumped by 85.75% to $2.1 million in 2017, then soared by 11880.19% to $248.1 million in 2019, then rose by 0.56% to $249.5 million in 2020.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $249.5 million, $230.5 million, and $248.1 million for Q4 2020, Q2 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 249.49 Mn |
| Jun 30, 2020 | 230.50 Mn |
| Dec 31, 2019 | 248.11 Mn |
| Jun 30, 2019 | 270.45 Mn |
| Dec 31, 2017 | 2.07 Mn |
| Dec 31, 2016 | 14.53 Mn |